随着Q3财报季走入尾声,全球制药巨头再次迎来“大洗牌”。礼来 凭借超过50%的营收增速强势登顶,成为本季度最亮眼的存在;同在GLP-1赛道的诺和诺德,曾于今年H1财报季进入跨国药企营收TOP10榜单,与礼来此刻的霸榜相呼应。相比之下,“昔日霸主”辉瑞却成为TOP10中唯一接连“双降”的企业。 强生 、默沙东、BMS同样增长乏力,整体呈现疲软态势。尽管几家欢喜几家愁,但一个共同的焦虑摆在多数MNC...
Source Link随着Q3财报季走入尾声,全球制药巨头再次迎来“大洗牌”。礼来 凭借超过50%的营收增速强势登顶,成为本季度最亮眼的存在;同在GLP-1赛道的诺和诺德,曾于今年H1财报季进入跨国药企营收TOP10榜单,与礼来此刻的霸榜相呼应。相比之下,“昔日霸主”辉瑞却成为TOP10中唯一接连“双降”的企业。 强生 、默沙东、BMS同样增长乏力,整体呈现疲软态势。尽管几家欢喜几家愁,但一个共同的焦虑摆在多数MNC...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.